key: cord-0940735-fgmzu3fi authors: MODI, Neena; AYRES-DE-CAMPOS, Diogo; BANCALARI, Eduardo; BENDERS, Manon; BRIANA, Despina; DI RENZO, Gian Carlo; FONSECA, Eduardo Borges; HOD, Moshe; POON, Liona; SANZ CORTES, Magda; SIMEONI, Umberto; TSCHERNING, Charlotte; VENTO, Maximo; VISSER, Gerard H.A.; VOTO, Liliana title: Equity in Covid-19 vaccine development and deployment date: 2021-01-15 journal: Am J Obstet Gynecol DOI: 10.1016/j.ajog.2021.01.006 sha: 838e94500f0ce20a6d9de430fd10ce5a08ecf48a doc_id: 940735 cord_uid: fgmzu3fi The COVID-19 pandemic exposed weaknesses in multiple domains and widened gender-based inequalities across the world. It also stimulated extraordinary scientific achievement, bringing vaccines to the public in under a year. In this article, we discuss the implications of current vaccination guidance for pregnant and lactating women, whether their exclusion from the first wave of vaccine trials was justified, and if a change in the current vaccine development pathway is necessary. Pregnant and lactating women were not included in initial SARS-CoV-2 vaccine trials. Perhaps unsurprisingly therefore, the first vaccine regulatory approvals have been accompanied by inconsistent advice from public health, governmental, and professional authorities around the world. Denying vaccination to women who though pregnant or breastfeeding are fully capable of autonomous decision-making is a throwback to a paternalistic era. Conversely, lack of evidence upon which to make an informed decision generated in a timely manner, shifts responsibility from research sponsors and regulators, and places the burden of decision-making upon a woman and her healthcare advisor. The World Health Organization (WHO), the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC), and others have highlighted the long-standing disadvantage experienced by women in relation to the development of vaccines and medicines. It is uncertain whether there was sufficient justification for excluding pregnant and lactating women from initial SARS-CoV-2 vaccine trials. In future, we recommend regulators mandate plans that describe the development pathway for new vaccines and medicines that address the needs of women who are pregnant or lactating. These should incorporate at the outset, careful consideration of the balance of risks of exclusion or inclusion from initial studies, patient and public perspectives, details of “Developmental and Reproductive Toxicity” studies, and approaches to collect data systematically from participants who are unknowingly pregnant at the time of exposure. This requires careful consideration of any prior knowledge of the mode of action of the vaccine and the likelihood of toxicity or teratogenicity. We also support the view that the default position should be a “presumption of inclusion”, with exclusion of women who are pregnant or lactating only if justified on specific, not generic, grounds. Finally, we recommend closer coordination across countries with the aim of issuing consistent public health advice. The year 2020, defined by COVID-19, will be book-marked as the moment in history when biomedical science demonstrated its growing mastery over infectious agents on a global scale. Identifying the causal pathogen, sequencing the SARS-CoV-2 genome, developing rapid diagnostic testing, optimizing treatments, generating vaccines, and commencing immunizations within a year, of first appearance of the disease, represents an extraordinary achievement. However, this accomplishment, as with other aspects of the response to the pandemic, has exposed weaknesses, in this case in the vaccine development pathway, and widened gender-based inequalities. As the first vaccines begin roll out in mass immunization programs, we discuss the implications of current vaccination guidance for pregnant and lactating women, whether their exclusion from the first wave of vaccine trials was justified, and if a change in the current vaccine development pathway is necessary. The UK was the first country to announce regulatory approval for a COVID-19 vaccine, the Pfizer-BioNTech mRNA product, on December 2, 2020. Given lack of evidence, the UK Joint Committee on Vaccination and Immunisation recommended a precautionary approach, advising against COVID-19 vaccination in pregnancy. 1 UK government advice published on December 6, to women who are pregnant, think they may be pregnant, or are planning to get pregnant was not to receive the vaccine, and advice to women who are breastfeeding was to wait until they have stopped breastfeeding before having the vaccine. 2 Revised advice published on December 18 made no mention of breastfeeding. 3 On December 30, the UK approved the use of the Oxford AstraZeneca vaccine and the Joint Committee on Vaccination and Immunisation issued further revisions to previous guidance. 4 They now advise that a pregnant woman who meets the definition of being clinically extremely vulnerable, or is a front-line worker, may discuss the option of COVID-19 vaccination with her doctor. They further advised breastfeeding women are eligible to receive the vaccines. Current UK recommendations regarding prioritization are to vaccinate frontline health and social care workers first, as well as those with conditions that place them at risk of more severe disease. 1 In the US, the Food and Drug Administration issued an "Emergency Use Authorization" for the Pfizer-BioNtech mRNA vaccine on December 11. This was followed, on December 13 by advice on "Vaccinating Pregnant and Lactating Patients Against COVID-19" from the American College of Obstetricians and Gynecologist's (ACOG) Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. 5 On December 15, the US-based Society for Maternal Fetal Medicine, a non-profit, membership organisation, recommended that pregnant and lactating women have access to COVID-19 vaccines. 6 In contrast with initial UK advice, the ACOG does not recommend withholding COVID-19 vaccines from women who are pregnant or lactating if they meet criteria for vaccination based on Advisory Committee on Immunization Practices priority group recommendations. The Advisory Committee on Immunization Practices also recommended prioritising health care workers and long-term care facility residents. 5 These recommendations exposed major problems. Approximately three quarters of frontline health and social care staff are women and of these, a substantial proportion are of childbearing age. Was the expectation that they should defer pregnancy until a vaccine is available? Even if this were the case, such advice would be unlikely to be effective given that around half of all pregnancies are unplanned. Pregnant women are also at risk of more severe disease than women who are not pregnant. This is the case for other viral infections, including influenza, swine flu, Ebola, MERS and SARS, as well as SARS-CoV-2. Pregnant women are more likely to require intensive care admission and ventilation, and to die, whether in high, middle or low-income countries. 7, 8 The exclusion of pregnant and lactating women from COVID-19 vaccination programmes in high-income countries will likely lead to much bigger effect in low and low middleincome countries where the majority of pregnancies occur, as local regulators are unlikely to take a different view. Women face other additional risks and inequities. They are more likely to contract infection from children, a group that will not receive the vaccine until much further down the line, because women still carry the major share of childcare responsibilities. Inconsistent recommendations such as these also place pregnant women and their physicians in an impossible situation. In the UK, pregnant and lactating women were initially unable to access the vaccine, so their choice was to stop work in order to shield, without guarantee of paid leave, or risk the disease. US guidance forces pregnant women to choose between voluntarily accepting the unknown risk of vaccine-associated harm in the knowledge that there will be no compensation should they suffer ill effects, and the risk of severe disease. In the UK, authorities initially advised women who were breastfeeding to choose between accessing the vaccine and stopping breastfeeding, or continuing breastfeeding and risking disease. This was an invidious situation, setting a woman's immediate wellbeing, against that of her baby, and against WHO and UK government advice to breastfeed for at least 6 months. In the US, the guidance places healthcare staff responsible for administering the vaccine in an equally difficult situation because without efficacy, effectiveness and safety studies in pregnant and lactating women, it is impossible to provide honest advice. Additionally, conflicting advice from, in this case, the UK and the US, and rapidly changing advice, damages public confidence in vaccine safety. This is a particular concern given the rising prevalence of anti-vaccine rhetoric and sentiment. The extrapolation of research conducted in men and non-pregnant women is potentially dangerous as immune responses and kinetics may differ substantially in pregnancy. The lack of data poses significant risks to the unborn baby. Vertical transmission of SARS-CoV-2 occurs, but appears rare and to-date, the effects on the developing fetus are unknown. [9] [10] [11] [12] [13] The traditional approach to vaccine and drug development is sequential. Here, researchers fist conduct efficacy trials in men and non-pregnant women and conduct follow-up of pregnancy outcomes when this occurs. If initial studies show efficacy, researcher sponsors conduct so-called bridging studies that include pregnant women. The rationale is that this stepwise approach protects pregnant women and their unborn children from risk during the early period of vaccine testing. The initial focus is on detection of potential signals of harm through observation, and toxicity and teratogenicity studies in animal models, the "Developmental and Reproductive Toxicity" (DART) studies. The downsides are that this approach delays vaccine delivery to women of childbearing age and a substantial proportion of first responders and essential workers remain unprotected. COVID-19 vaccine developers appear to have adopted the traditional approach even though regulators considered this unnecessary during the Ebola and Zika outbreaks. 14 Vaccination during pregnancy is routine for tetanus, diphtheria, pertussis and hepatitis B, but not for live vaccines. However, the SARS-CoV-2 vaccines are not live. The Johnson and Johnson SARS-CoV-2 vaccine is adenovirus-based, as is the company's Ebola vaccine, used in pregnancy and considered safe. Messenger RNA (mRNA) vaccines are relatively new. They consist of mRNA encapsulated in a lipid nanoparticle that stimulate generation of the coronavirus spike protein, which in turn stimulates the production of anti SARS-CoV-2 antibodies. The mRNA vaccines do not contain live virus, do not enter the nucleus and do not alter human DNA. 15 The ACOG therefore concluded that it would be unlikely that the safety and efficacy profile of the vaccine differed between women who are pregnant and those who are not. At the time of writing, regulators anticipate receiving data imminently from initial animal reproductive toxicity studies conducted by Pfizer. Data from studies in animal models raised concerns of a theoretical risk for COVID-19 vaccineassociated enhanced respiratory disease. This informed recommendations to exclude participants at higher risk of severe COVID-19 from early-phase studies until additional data are available. The exclusion of pregnant women from early vaccine trials may therefore have possibly been justifiable on the grounds of greater risk of vaccine-associated enhanced respiratory disease. However, this does not appear to be justification for excluding lactating women. Traditional practice considers women and children to be "vulnerable groups" who are in need of enhanced protection from the dangers of research. This view has its origins in the research abuses of the first half of the last century, and the recognition of the possibility of adverse fetal effects. Many groups have since questioned the blanket imposition of this well-intentioned, but nonetheless paternalistic attitude. Recent decades have also seen the evolving recognition of clinical research as an integral component of good patient care. In this, patients have a right to be protected (from non-evidenced practice) "through research", as opposed to protected from (the dangers) "of research". Thus, the exclusion of so-called vulnerable groups has also meant that evidence of efficacy, safety, pharmacokinetics and pharmacodynamics has been lacking, leaving these groups vulnerable to harm, instead of providing protection. Hence, for example, the extent to which antibody-dependent enhancement may be a factor in pregnant and lactating women and newborns is unknown. 16, 17 This shift in perspective gained ground in the 1980s and 1990s when for example, women's health groups and Acquired Immune Deficiency Syndrome advocates drew attention to inequities in the research agenda and organisations such as the British Paediatric Association in the UK voiced support for the inclusion of children in clinical research. 18 In 1994, the US Institute of Medicine (now National Academy of Medicine) published a report entitled "Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies". Current guidance is for a "presumption of inclusion", where inclusion is the default unless there are clear reasons that justify exclusion. 14, 19 Additionally, the World Health Organisation has highlighted the need for COVID-19 vaccine data specific to pregnancy noting they "warrant particular consideration", as they have been long disadvantaged with respect to the development and deployment of vaccines. They say "It is imperative that data specific to pregnancy be generated now from, for example, pregnancy-specific safety and bridging studies and from participants who inadvertently become pregnant during Phase III trials". The World Health Organisation also state, "Vaccine developers and funders should prioritize an assessment of vaccine safety and immunogenicity among pregnant women in their clinical development and of safety and effectiveness in post-marketing surveillance plans". 20 The US Department of Health and Human Services' FDA Center for Biologics Evaluation and Research issued non-binding guidance for industry in June 2020 in "Development and Licensure of Vaccines to Prevent COVID-19." 21 In this report, they cite their April 2018 guidance, "Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials Guidance for Industry", which however, remains in draft. 22 Recently, the 21st Century Cures Act established the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) to advise the Secretary of Health and Human Services regarding gaps in knowledge and research on safe and effective therapies for pregnant women and lactating women, and support their inclusion in clinical and translational research. 23, 24 Concerns about the exclusion of pregnant and lactating women are also growing around the world. 25, 26 Conclusions Current vaccination guidance is inconsistent across countries. The consequences are serious, farreaching, and damaging to women, their babies and wider society. Inconsistent guidance creates anxieties in the public mind and is likely to fuel anti-vaccine sentiment. It either places the burden of decision-making upon women and their healthcare providers without information to assist in making an informed choice or imposes a paternalistic decision without the involvement of the women themselves. In the face of an unprecedented pandemic, research sponsors and regulators could have considered data from relevant DART studies in reaching a view about the inclusion of these groups in first phase trials and put in place mechanisms to obtain data systematically from women inadvertently vaccinated in pregnancy. As we write, we are pleased to note that trials commencing in 2021 will include pregnant and lactating women, but we ask whether the delay in obtaining evidence relevant to their needs, was justified. Going forward, we recommend first, that regulators mandate the development of "pregnancyinvestigation plans" that describe the development pathway for vaccines and medicines that will be used in pregnancy, in an approach analogous to the European Medicines Agency "Paediatric Investigation Plans" for medicines used in children. 27 Such plans should incorporate at the outset, careful consideration of the balance of risks of excluding or including pregnant and lactating women from initial studies. This requires consideration of any prior knowledge of the mode of action of the vaccine or medication and the likelihood of toxicity or teratogenicity. The development plan should include the close involvement of patient and public perspectives, initiate DART studies at the outset, and set out approaches to collect data systematically on immunogenicity and pregnancy-specific indicators of safety from participants who are unknowingly pregnant at the time of exposure or become pregnant shortly following vaccine administration. Second, we support the view that the a priori, default position should be a "presumption of inclusion", with exclusion only if justified on specific, not generic, grounds. Third, we recommend closer collaboration before new vaccine release, ideally coordinated by the World Health Organisation, with the aim of issuing consistent advice across countries. Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI COVID-19 vaccination: a guide for women of childbearing age, pregnant, planning a pregnancy or breastfeeding 19-vaccines-when-given-in-pregnancy/the-safety-of-covid-19-vaccines-when-given-inpregnancy UK Joint Committee on Vacdination and Immunisation, Published American College of Obstetricians and Gynecologists, Vaccinating Pregnant and Lactating Patients Against COVID-19 Provider Considerations for Engaging Vaccine Counselling With Pregnant and Lactating Patients CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States Pregnant women with SARS-CoV-2 infection are at higher risk of death and severe pneumonia: propensity score-matched analysis of a nationwide prospective cohort study Online ahead of print 9 Transplacental transmission of SARS-CoV-2 infection Evidence for and against vertical transmission for SARS-CoV-2 (COVID-19) Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy Pregnant women and vaccines against emerging epidemic threats: ethics guidance for preparedness, research, and response Advances in mRNA Vaccines for Infectious Diseases Virgin HW A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Dissecting antibody-mediated protection against SARS-CoV-2 British Paediatric Association Working Party on Ethics of Research in Children. Guidelines to aid ethical committees considering research involving children Pregnant Women & Vaccines Against Emerging Epidemic Threats: Ethics Guidance for Preparedness, Research, and Response WHO-SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of a limited supply: An approach to inform planning and subsequent recommendations based upon epidemiologic setting and vaccine supply scenarios Version 1 Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials Guidance for Industry Women Must Be Included in Medical Research Scientific American Breastfeeding mothers will not be offered COVID vaccine The Guardian The authors are founding members of the International Foundation for "Maternal, Periconceptional and Peri-Neonatal Medicine" whose purpose is to foster global education, research and advocacy in maternal, periconceptional and neonatal medicine. NM wrote the first draft of the paper; all authors reviewed and agreed the final version submitted Disclosures: NM is the immediate past-president of the UK Royal College of Paediatrics and Child Health, the current president of the UK Medical Women's Federation, and president-elect of the British Medical Association. GDR is the president of the International Foundation for "Maternal, Peri-conceptional and Peri-Neonatal Medicine." All views expressed are their own.